Navigation Links
Leading Financial Analyst Group Estimates 5-Year Revenue for HRID at $42MM
Date:3/19/2012

FORT LAUDERDALE, Fla., March 19, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals, soon to be changed from Hybrid Fuels, Inc., (Pink Sheets: HRID) announced today that Advent Financial, a leading financial analyst group focused on small and micro-cap companies, estimated next 5-year revenue for the Company at $42MM.  Advent has a very qualified team of research analysts with extensive experience at large investment banks including Bank of America, Goldman Sachs, and UBS Warburg.

As published in the analyst report in the projections and valuation section, Advent estimated next 5-year revenue for the Company at $42MM using the following assumptions: a) Company will steadily increase its distribution footprint by signing agreements with national pharmacy chains; b) Over the next five years, Azul Instant™ will be available at 35% of all retail outlets managed by the national pharmacy chains.  Agreements with traditional retailers will provide further upside to our revenue estimate; c) Average revenue per store will increase from $300/month in 2012 to $500/month by 2013.

To view the report in its entirety, please visit: http://www.adventfinancialinc.com/research/index.php under recent reports.

About Azul Instant™

Azul Instant™ was developed by the scientific research and development team of Nouveau Life Pharmaceuticals to provide a safe and natural alternative for the millions of men suffering from erectile dysfunction.  The Company's goal is to create the healthiest and most effective all-natural male enhancer ever formulated.  Patients will now receive the NATURAL benefits of Azul Instant™ and unlike pharmaceutical drugs such as Cialis, Viagra and Levitra, Azul Instant™, carries no dangerous side effects.  While there are other natural alternative supplements on the market today, Azul Instant™ is the only male enhancement product that works as fast as 5 minutes.  Azul Instant™ can last for up to 48 hours and has proven to help enhance sexual stamina, endurance, strength and energy with no side effects. 

Azul Instant™ is marketed under Nouveau Life Pharmaceuticals, Inc.  For more information, go to www.azulnow.com

About Hybrid Fuels, Inc.

The company was incorporated in the state of Nevada in 1998 as Polo Equities.  It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies. 

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Hybrid Fuels, Inc. undertakes no obligation to update such statements.

CONTACT:

Nouveau Life Pharmaceuticals, Inc. - 954-903-2993


'/>"/>
SOURCE Nouveau Life Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hemostasis Diagnostics Market Leading Suppliers and Emerging Market Entrants
2. Leading Cardiovascular Organizations Release Credentialing Recommendations for Heart Valve Replacement Procedure
3. Qmed, the Leading Global MedTech Industry Resource, Partners with onTargetjobs to Provide Medical Device Professionals and Employers with Career Services Tool
4. Leading Industry Multinationals Participate in Medical Device Costa Rica Panel: "Developing a Strong Supplier Base"
5. Acuo Technologies Announces Another Significant Growth Year in Sales to Further the Companys Market Leading Position
6. Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company
7. Leading Antitrust Senator Raises Serious Doubts About Proposed Express Scripts-Medco PBM Merger
8. ThermoGenesis Provides Update on Res-Q® Clinical Evaluations at Leading Stem Cell Therapy Conference
9. Worlds Leading Pharmaceutical Executives All Converging in Zurich, Switzerland on February 21-22, 2012 for Breakthrough Event
10. Niiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists
11. International Panel of Leading Bariatric Surgeons Reaches Consensus on Optimal Techniques for Laparoscopic Sleeve Gastrectomy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):